• STAT+: Pharmalittle: Most doctors disagree with FDA approval of the new Alzheimer's drug; women underrepresented in life sciences C-suites

    2 monthes ago - By STAT

    Good morning, everyone, and how are you today? The heat continues to rise here on the Pharmalot campus, where we are hoping for storm clouds to wash away the humidity that has characterized the past few days. One can dream, yes? To cope, we are quaffing some cups of stimulation and distracting ourselves by foraging for items of interest. Toward that end, we have assembled a few below. Hope you find these helpful and have a cool day. Keep in touch....
    A majority of U.S. physicians disagree with the Food and Drug Administration's approval of the Alzheimer's drug from Biogen and believe the...
    Read more ...

     

  • STAT+: Revised analysis nudges up cost-effective price for Biogen's Alzheimer's drug to $3,000 to $8,400 a year

    2 monthes ago - By STAT

    The controversial new Alzheimer's drug from Biogen would be cost-effective only if priced between $3,000 and $8,400, which represents an 85% to 95% discount off the $56,000 list price, due to “insufficient” evidence the drug benefits patients, according to a revised analysis.
    The assessment is very similar to an evaluation that was issued last month, before the Food and Drug Administration approved the medicine and issued a broad label. This means the medication can be prescribed to potentially millions of patients, regardless of the extent of their disease, even though Biogen tested its...
    Read more ...